Adrian M. Di Bisceglie

Adrian M. Di Bisceglie's AcademicInfluence.com Rankings

Philosophy

#5903

World Rank

#8834

Historical Rank

Logic

#3117

World Rank

#4228

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Adrian M. Di Bisceglie's Degrees

Doctorate Medicine University of Buenos Aires

Why Is Adrian M. Di Bisceglie Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Adrian M. Di Bisceglie's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Telaprevir for previously untreated chronic hepatitis C virus infection. (2011) (2539)
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. (2014) (1329)
Design and endpoints of clinical trials in hepatocellular carcinoma. (2008) (1216)
Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. (1989) (1214)
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. (2014) (1153)
Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. (1991) (1152)
Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. (1986) (1002)
Telaprevir for previously treated chronic HCV infection. (2010) (769)
Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease (2008) (661)
Hepatocellular carcinoma: diagnosis and treatment. (2002) (606)
Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis (1991) (579)
Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. (1995) (566)
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (2014) (518)
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. (2004) (501)
Outcome of sustained virological responders with histologically advanced chronic hepatitis C (2010) (500)
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. (2009) (484)
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. (2010) (442)
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5‐year follow‐up of 150 patients (2009) (422)
NIH conference. Hepatocellular carcinoma. (1988) (421)
Long-term remission of chronic hepatitis B after alpha-interferon therapy. (1991) (402)
Measurements of iron status in patients with chronic hepatitis. (1992) (390)
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. (2010) (389)
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. (2008) (381)
Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. (1994) (381)
Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. (2000) (380)
Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. (1991) (379)
A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. (2010) (371)
Diagnosis of hepatocellular carcinoma. (2005) (369)
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT‐C cohort (2005) (354)
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. (2005) (335)
Telbivudine versus lamivudine in patients with chronic hepatitis B. (2007) (322)
Optimal therapy of hepatitis C (2002) (303)
A pilot study of ribavirin therapy for chronic hepatitis C (1992) (300)
Ribavirin as Therapy for Chronic Hepatitis C (1995) (263)
Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. (1995) (257)
Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. (1990) (249)
The significance of antibody to hepatitis C virus in patients with chronic hepatitis B (1991) (247)
The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. (2005) (240)
Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules (1995) (240)
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. (2010) (236)
Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. (1992) (236)
Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north america (1998) (235)
Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. (1989) (227)
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. (2007) (219)
Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. (1993) (216)
Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. (1991) (210)
Genotypic analysis of hepatitis C virus in American patients (1994) (209)
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. (2016) (206)
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. (2005) (192)
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. (2011) (188)
Long‐term follow‐up of patients with chronic hepatitis C treated with α‐interferon (1992) (181)
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay (2008) (179)
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. (2016) (178)
Serologic diagnosis of acute and chronic viral hepatitis. (1991) (177)
Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-2b (2009) (176)
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. (1995) (175)
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C (2009) (172)
Hepatitis C viral RNA in serum of patients with chronic non‐A, non‐B hepatitis: Detection by the polymerase chain reaction using multiple primer sets (1991) (172)
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT‐C trial (2006) (172)
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. (2004) (172)
Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B (1993) (170)
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C (2011) (163)
Natural history of hepatitis C: Its impact on clinical management (2000) (162)
Hepatitis C Virus Infection in the Mothers and Infants Cohort Study (1998) (162)
Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification. (1992) (160)
The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. (1991) (159)
Elevations in serum alpha‐fetoprotein levels in patients with chronic hepatitis B (1989) (157)
Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial (2000) (152)
New therapeutic strategies for hepatitis C (2002) (150)
Herbal product use by persons enrolled in the hepatitis C Antiviral Long‐Term Treatment Against Cirrhosis (HALT‐C) Trial (2007) (148)
Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular Carcinoma (2009) (144)
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. (2007) (141)
Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells (2017) (129)
Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. (1999) (125)
Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy (2007) (116)
Geographic distribution and genetic variability of hepatitis delta virus genotype I. (1997) (113)
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis (2005) (113)
Linkage Specific Fucosylation of Alpha-1-Antitrypsin in Liver Cirrhosis and Cancer Patients: Implications for a Biomarker of Hepatocellular Carcinoma (2010) (113)
Telbivudine improves renal function in patients with chronic hepatitis B. (2014) (108)
Combination of interferon and ribavirin in chronic hepatitis C: Re‐treatment of nonresponders to interferon (2001) (107)
The effect of cholesterol‐lowering agents on hepatic and plasma cholesterol in Niemann‐Pick disease type C (1993) (106)
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. (2006) (103)
Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. (2005) (102)
Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. (1992) (100)
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. (2006) (98)
The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. (2008) (96)
Early virologic response after peginterferon alpha‐2a plus ribavirin or peginterferon alpha‐2b plus ribavirin treatment in patients with chronic hepatitis C * (2007) (94)
Testing for Hepatitis C Virus Infection Should Be Routine for Persons at Increased Risk for Infection (2004) (94)
Recurrence of hepatitis C virus infection after orthotopic liver transplantation (1991) (92)
Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. (1998) (91)
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. (2010) (91)
Hepatitis C Virus Infection Modulates Expression of Interferon Stimulatory Gene IFITM1 by Upregulating miR-130A (2012) (91)
Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. (1994) (90)
Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. (1989) (88)
Serum miR-30e and miR-223 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma. (2016) (87)
Effects of iron loading on pathogenicity in hepatitis C virus–infected chimpanzees (1999) (87)
Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. (2006) (86)
Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. (1988) (84)
Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. (1992) (82)
Epidemiology and clinical presentation of hepatocellular carcinoma. (2002) (80)
Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. (1995) (80)
Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics: Randomized study of higher doses of peginterferon α‐2a and ribavirin (2008) (80)
Variants in interferon‐alpha pathway genes and response to pegylated interferon‐Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long‐term treatment against cirrhosis trial (2009) (79)
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C (2011) (79)
Hepatitis C Virus Proteins Inhibit C3 Complement Production (2011) (77)
Absence of hepatitis C viral RNA from saliva and semen of patients with chronic hepatitis C. (1992) (77)
Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency. (2012) (76)
Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases (1995) (76)
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study (2016) (75)
Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. (2006) (75)
Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. (2015) (75)
Diabetic hepatosclerosis: diabetic microangiopathy of the liver. (2006) (75)
Gaucher disease: abdominal MR imaging findings in 46 patients. (1992) (75)
Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. (2009) (74)
A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. (1993) (71)
Hepatitis C Virus-Mediated Enhancement of MicroRNA miR-373 Impairs the JAK/STAT Signaling Pathway (2015) (70)
Changes in hepatitis C virus antigen in liver with antiviral therapy. (1993) (69)
Hepatitis C virus replication during acute infection in the chimpanzee. (1992) (69)
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. (2020) (69)
Accumulation of B Lymphocytes with a Naive, Resting Phenotype in a Subset of Hepatitis C Patients 1 (2003) (68)
Liver transplantation for hepatocellular carcinoma. (2005) (67)
Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. (1994) (67)
HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. (2004) (65)
High levels of viral replication during acute hepatitis B infection predict progression to chronicity (1994) (63)
Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study. (1985) (62)
Mutations of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. (1992) (62)
Determination of hepatitis B virus DNA in serum using the polymerase chain reaction: Clinical significance and correlation with serological and biochemical markers (1991) (61)
Evolution of hepatitis C viral quasispecies after liver transplantation. (2001) (61)
Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. (1997) (61)
Hepatitis C Virus Induces Epithelial-Mesenchymal Transition in Primary Human Hepatocytes (2012) (60)
Therapy of chronic hepatitis b with recombinant human alpha and gamma interferon (1990) (59)
Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long‐term treatment against cirrhosis (HALT‐C) trial (2009) (58)
Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States (2007) (57)
Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma (2012) (57)
Multifocal verruciform xanthoma of the upper aerodigestive tract in a child with a systemic lipid storage disease. (1989) (57)
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. (2006) (55)
Issues in screening and surveillance for hepatocellular carcinoma. (2004) (55)
Pruritus as a Presenting Symptom of Chronic Hepatitis C (1998) (54)
Transcriptional Repression of C4 Complement by Hepatitis C Virus Proteins (2011) (54)
Seizures during alpha interferon therapy. (1996) (54)
Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy. (1987) (53)
Screening in liver disease: Report of an AASLD clinical workshop (2004) (52)
Antiviral therapy of hepatitis C--present and future. (1993) (51)
HCV RNA detection by TMA during the hepatitis C antiviral long‐term treatment against cirrhosis (Halt‐C) trial (2006) (50)
Therapy of chronic hepatitis C with α‐interferon: The answer? Or more questions? (1991) (50)
Complement-Mediated Enhancement of Antibody Function for Neutralization of Pseudotype Virus Containing Hepatitis C Virus E2 Chimeric Glycoprotein (2002) (50)
The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesis. (2005) (50)
All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database (2017) (50)
Clinical presentation and natural course of hepatocellular carcinoma. (2005) (48)
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. (2007) (47)
High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy (2009) (47)
GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study (2016) (47)
Determination of hepatitis B phenotype using biochemical and serological markers (2017) (46)
Primary lymphoma of the liver in a patient with acquired immune deficiency syndrome and chronic hepatitis B. (1989) (46)
Cholesteryl ester storage disease: Hepatopathology and effects of therapy with lovastatin (1990) (46)
Optimal therapy of hepatitis C (2002) (46)
Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: a case report. (2005) (43)
Infection with Hepatitis C Virus Genotype 4 in the United States (2004) (43)
Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Application for clinical diagnosis. (1990) (43)
Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis (1994) (43)
Therapy of chronic hepatitis B with a 6-month course of ribavirin. (1994) (42)
HIV-HBV coinfection among South African patients receiving antiretroviral therapy. (2010) (42)
Seroprevalence of Viral Hepatitis in an Older Nursing Home Population (1999) (42)
The physical state of the negative strand of hepatitis C virus RNA in serum of patients with chronic hepatitis C. (1994) (41)
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. (2010) (41)
Increased Hepatic Oxidative DNA Damage in Patients with Hepatocellular Carcinoma (2001) (41)
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. (2016) (41)
Hepatitis C Virus Suppresses C9 Complement Synthesis and Impairs Membrane Attack Complex Function (2013) (40)
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C (2005) (38)
Cryoglobulinemia associated with Purtscher-like retinopathy. (2001) (38)
Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients (2010) (37)
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. (2009) (37)
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes (2015) (36)
A pilot study of 2′,3′‐dideoxyinosine for the treatment of chronic hepatitis B (1992) (35)
Treatment of chronic type C hepatitis with alpha interferon. (1989) (35)
Novel Changes in Glycosylation of Serum Apo-J in Patients with Hepatocellular Carcinoma (2011) (35)
Diagnosis of hepatitis delta virus infection (1989) (35)
Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis. (2007) (35)
RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus (1994) (34)
Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. (1991) (34)
Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. (2014) (33)
Spontaneous retroperitoneal and rectus muscle hemorrhage as a potentially lethal complication of cirrhosis (2006) (32)
Excess mortality in patients with advanced chronic hepatitis C treated with long‐term peginterferon (2011) (32)
Hepatitis C Virus Infection Upregulates CD55 Expression on the Hepatocyte Surface and Promotes Association with Virus Particles (2013) (31)
Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study. (2019) (31)
Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma (1994) (30)
Liver transplantation with hepatitis C virus‐infected graft: Interaction between donor and recipient viral strains (2003) (30)
Detection of alpha-foetoprotein messenger RNA in human hepatocellular carcinoma and hepatoblastoma tissue. (1986) (30)
Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine (2000) (29)
Evidence for probable sexual transmission of the hepatitis g virus. (2002) (29)
Is hepatitis G/GB virus‐C virus hepatotropic? Detection of hepatitis G/GB virus‐C viral RNA in liver and serum (1999) (29)
Biliary‐Venous Fistula Complicating Transjugular Intrahepatic Portosystemic Shunt Presenting With Recurrent Bacteremia, Jaundice, Anemia and Fever (2003) (29)
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir (2015) (29)
Therapy of chronic delta hepatitis with interferon alfa-2b. (1990) (28)
Management of chronic viral hepatitis in children. (1995) (28)
Changes in quality of life and sexual health are associated with low‐dose peginterferon therapy and disease progression in patients with chronic hepatitis C (2010) (28)
Intrahepatic markers of hepatitis delta virus infection: a study by in situ hybridization. (1989) (28)
Viral hepatitis and hepatocellular carcinoma. (1994) (28)
Hepatic alpha-smooth muscle actin expression in hepatitis C patients before and after interferon therapy. (2001) (27)
A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis. (1990) (27)
Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. (1992) (27)
Aging liver and hepatitis. (2007) (26)
A common staging system for hepatocellular carcinoma (2004) (26)
Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: The null responder (2006) (25)
Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. (2019) (24)
Chronic fatigue syndrome: Lack Of association with hepatitis C virus infection (1991) (24)
Absence of hepatitis C viral infection among patients with primary Sjögren's syndrome. (1995) (24)
Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis. (2004) (23)
Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection (2013) (23)
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. (2020) (23)
Diagnosis of chronic hepatitis C: comparison of immunoassays and the polymerase chain reaction. (1994) (23)
B‐cell epitopes on the hepatitis C virus nucleocapsid protein determined by human monospecific antibodies (1993) (22)
Lack of association between genotypes and subtypes of HCV and occurrence of hepatocellular carcinoma in Egypt (2009) (22)
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study (2018) (22)
Comparative Analysis of Nearly Full-Length Hepatitis C Virus Quasispecies from Patients Experiencing Viral Breakthrough during Antiviral Therapy: Clustered Mutations in Three Functional Genes, E2, NS2, and NS5a (2008) (22)
Rapid development of hepatic alpha1-antitrypsin globules after liver transplantation for chronic hepatitis C. (1997) (21)
Current and Future Systemic Therapies for Hepatocellular Carcinoma. (2019) (21)
Molecular and serological aspects of HBsAg‐negative hepatitis B virus infections in North America (2003) (21)
Hepatocyte senescence in end‐stage chronic liver disease: a study of cyclin‐dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma (2007) (21)
Hepatitis C Virus-Mediated Inhibition of Cathepsin S Increases Invariant-Chain Expression on Hepatocyte Surface (2012) (21)
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes (2021) (20)
Hepatitis C and hepatocellular carcinoma (1997) (20)
A comparison between the phenol-chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of hepatitis C and GB virus-C/hepatitis G viral RNA from serum. (2000) (20)
Inhibition of C3 Convertase Activity by Hepatitis C Virus as an Additional Lesion in the Regulation of Complement Components (2014) (19)
Hepatitis B and hepatocellular carcinoma (2009) (19)
Hepatocellular carcinoma: molecular biology of its growth and relationship to hepatitis B virus infection. (1989) (19)
Pretransplant treatments for hepatocellular carcinoma: Do they improve outcomes? (2005) (18)
A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables (2013) (18)
High-Resolution Quantification of Hepatitis C Virus Genome-Wide Mutation Load and Its Correlation with the Outcome of Peginterferon-Alpha2a and Ribavirin Combination Therapy (2014) (18)
Chemoprevention of hepatocellular carcinoma: use of tamoxifen in an animal model of hepatocarcinogenesis. (2005) (18)
The treatment of chronic viral hepatitis. (1997) (17)
Hepatitis B virus replication within the human spleen (1990) (17)
Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samples (2006) (17)
Detection and quantitation of hepatitis C virus RNA in serum using the polymerase chain reaction and a colorimetric enzymatic detection system. (1994) (16)
Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B. (1996) (16)
Combination therapy for hepatitis B (2002) (16)
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy (2020) (16)
Hepatitis G Virus Infection: A Work in Progress (1996) (16)
Treatment of chronic type B hepatitis. (1989) (15)
Delayed recurrence of hepatocellular carcinoma after liver transplantation: Detection of origin by chromosomal analysis (2000) (15)
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection (2014) (15)
Differential Expression of MicroRNAs in Hepatitis C Virus-Mediated Liver Disease Between African Americans and Caucasians: Implications for Racial Health Disparities. (2017) (14)
Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus (2016) (14)
Antiviral therapy of chronic viral hepatitis. ACG Committee on FDA-Related Matters. (1990) (14)
The unmet challenges of hepatitis C. (1999) (14)
Detection and Quantification of Hepatitis C Virus (HCV) by MultiCode-RTx Real-Time PCR Targeting the HCV 3′ Untranslated Region (2009) (14)
Separation of near full-length hepatitis C virus quasispecies variants from a complex population. (2007) (14)
Template-dependent multiple displacement amplification for profiling human circulating RNA. (2017) (14)
Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B (2019) (13)
Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy (2018) (13)
The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. (2005) (13)
Oligoclonal immunoglobulin bands in serum in association with chronic viral hepatitis. (1990) (13)
Differential amplification of hypervariable region 1 of hepatitis C virus by partially mismatched primers. (2001) (13)
Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. (1997) (13)
The genesis of chronic pancreatitis in the South African black population. (1988) (13)
Molecular biology and clinical implication of hepatitis C virus. (2004) (12)
Phenotypes of Chronic Hepatitis B in Children from a Large North American Cohort. (2019) (12)
Therapy of chronic hepatitis C with alpha-interferon: the answer? Or more questions? (1991) (12)
Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. (2019) (12)
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. (2017) (12)
Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics (2011) (12)
What every hepatologist should know about endocrinology: obesity, diabetes, and liver disease. (2004) (11)
Distribution of hepatitis B virus (HBV) genotypes among patients with acute viral hepatitis. (2005) (11)
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis (2020) (11)
Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis (2005) (11)
Evidence for action of ribavirin through the hepatitis C virus RNA polymerase (2009) (11)
Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa‐2a/ribavirin in chronic hepatitis C (2010) (11)
RT-PCR amplification and cloning of large viral sequences. (2010) (10)
Clinical decisions. Management of incidental hepatitis C virus infection. (2009) (10)
Liver transplantation for hepatitis C: The promise and the challenge (1995) (10)
Interferon therapy for chronic viral hepatitis. (1994) (10)
Myocardial infarction in an intensive care unit for blacks. A review over 6 years. (1982) (10)
Antigen‐specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C (2012) (9)
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis (2019) (9)
Expression of P-Glycoprotein and C-MOAT in Human Hepatocellular Carcinoma: Detection by Immunostaining (2002) (8)
A 35-year-old woman with progesterone implant contraception and multiple liver masses. (2001) (8)
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia (2020) (8)
Hepatocellular carcinoma (1998) (8)
Hepatocellular carcinoma not related to hepatitis B virus infection among Alaska natives. (1999) (8)
Correction for Devhare et al., “Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells” (2017) (8)
Hepatitis C viral RNA in serum of patients with chronic non-A, non-B hepatitis: detection by the polymerase chain reaction using multiple primer sets. (1992) (7)
Benign extrinsic oesophageal dysphagia. Case reports. (1985) (7)
Nodular Regenerative Hyperplasia of the Liver in Idiopathic Hypereosinophilic Syndrome (1991) (7)
The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. (2006) (7)
Screening for hepatocellular carcinoma: being old is not all bad. (2004) (7)
Long-term outcome of interferon-alpha therapy for chronic hepatitis B. (1995) (7)
Massive intrahepatic hemorrhage following routine liver biopsy in a patient with rheumatoid arthritis treated with methotrexate. (1992) (7)
Factors predisposing to central corneal ulceration in a developing population. (1987) (6)
Diversification of hypervariable region 1 of hepatitis C virus after liver transplantation (2003) (6)
Prolonged alpha interferon therapy for chronic delta hepatitis: effect on liver histopathology. (1993) (6)
Idiopathic CD4+ T‐lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men (1995) (6)
The development of a mutation in the precore region of the hepatitis B virus in a chronically infected individual. (1994) (6)
Patient‐reported outcomes 12 months after hepatitis C treatment with direct‐acting antivirals: Results from the PROP UP study (2021) (6)
Bacterial endocarditis due to an infected peritoneal dialysis catheter. A case report. (1983) (6)
Expression of c-myc Promoter Binding Protein (MBP-1), a Novel Eukaryotic Repressor Gene, in Cirrhosis and Human Hepatocellular Carcinoma (2001) (6)
Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases. (1999) (5)
Detection of markers of hepatitis B virus infection in urine of chronic carriers (1985) (5)
Interferon therapy of complicated hepatitis B virus infection. (1989) (5)
Images in clinical medicine. Vasculitis and cryoglobulinemia related to hepatitis C. (1994) (5)
Genetic characterization of hypervariable region 1 in patients chronically infected with hepatitis C virus genotype 2 (2001) (5)
Continuous peritoneal dialysis in a developing population--problems seen at Baragwanath Hospital. (1983) (5)
Direct evidence for GB virus C/hepatitis G virus (GBV‐C/HGV) superinfection: Elimination of resident viral strain by donor strain in a patient undergoing liver transplantation (2002) (5)
Management of post-transfusion hepatitis. (1988) (4)
Viral categorization and discovery in human circulation by transcriptome sequencing. (2013) (4)
Hepatitis C--virology and future antiviral targets. (1999) (4)
Understanding the natural history of chronic HBV and HCV infections. (2010) (4)
Correction: A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables (2013) (4)
The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma. (2011) (4)
Pancreatic endocrine tumor presenting with obstructive jaundice. (1984) (4)
Alpha interferon therapy of chronic delta hepatitis: a pilot study. (1991) (4)
Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation. (2011) (4)
Hyponatraemia complicating the treatment of myxoedema coma. A case report. (1986) (3)
Enhanced protocol for determining the 3' terminus of hepatitis C virus. (2010) (3)
HCV Genome-Wide Genetic Analyses in Context of Disease Progression and Hepatocellular Carcinoma (2014) (3)
Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study (2021) (3)
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study (2021) (3)
Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy. (2016) (3)
Comprehensive cloning of patient-derived 9022-bp amplicons of hepatitis C virus. (2013) (3)
Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA (2007) (3)
Therapy of chronic delta hepatitis: overview. (1993) (3)
In-depth serum virome analysis in patients with acute liver failure with indeterminate etiology (2019) (3)
Long term follow up of bone mineral density in patients with primary biliary cirrhosis. (2004) (3)
Preventive strategies for chronic liver disease. (2001) (3)
A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC (2020) (2)
A 32-year-old man with hepatitis C who developed progressive liver failure after a bone marrow transplant. (2002) (2)
Phaeochromocytoma. Case reports. (1982) (2)
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)". (2019) (2)
Detection of hepatitis C viral RNA in serum of a patient with acute non A, non B hepatitis. (1991) (2)
Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterferon alpha-2a Plus Ribavirin and the Benefit-Risk Ratio of Retreatment (2013) (2)
Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B (1995) (2)
Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy (2020) (2)
HALT‐C trial (2002) (2)
CD81 binding regions of hepatitis C virus remain conserved after liver transplantation. (2004) (1)
A randomized, double blind, placebo-controlled trial of htd1801 (berberine ursodeoxycholate, budc) in patients with hypercholesterolemia: implications for its use in non-alcoholic steatohepatitis (NASH) (2020) (1)
Prevention of hepatocellular carcinoma with antiviral therapy. (2018) (1)
Prevention of hepatocellular carcinoma resulting from hepatitis B: are we there yet? (2014) (1)
The liver in biliary obstruction due to chronic pancreatitis. (2008) (1)
SEN and sensibility: interactions between newly discovered and other hepatitis viruses? (2001) (1)
Multiple myeloma and pernicious anaemia. A case report. (1982) (1)
Obstructive jaundice in the South African black population. (1986) (1)
Changes in Health for Patients Who Complete Treatment for Chronic Hepatitis C Virus -- The PROP up TARGET Study (2020) (1)
Within-host quantitation of anellovirus genome complexity from clinical samples. (2022) (1)
A new approach to therapy for hepatocellular carcinoma? (2003) (1)
HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. (2019) (1)
Hepatitis C and hepatocellular carcinoma. (1995) (1)
A 20-year-old man with persistent aminotransferase elevations. (1991) (1)
Transudative ascites with a high protein content. Case reports. (1985) (1)
Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. (2023) (0)
A novel target enrichment strategy in next-generation sequencing through 7-deaza-dGTP-resistant enzymatic digestion (2020) (0)
Plasmodium falciparum malaria in the southern Transvaal. (1985) (0)
A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis (2022) (0)
Hepatitis C. (1998) (0)
Reply (2002) (0)
An error rationalised is still a mistake. (2002) (0)
Ribavirin for Chronic Hepatitis C (1996) (0)
Chronic hepatitis B. Hope for decreasing its impact. (1995) (0)
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites (2021) (0)
Thymus-derived peptides for chronic viral hepatitis: have they fulfilled their promise? (1996) (0)
A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables (2013) (0)
Does bare-stent TIPS increase the risk of hepatocellular carcinoma in patients with cirrhosis? (2005) (0)
The history of the Department of Internal Medicine at Saint Louis University. (2012) (0)
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia (2020) (0)
Meet Your President: Michael W. Fried, M.D., F.A.A.S.L.D. (2019) (0)
The AASLD and public policy: Coming in out of the cold (2007) (0)
Hepatitis C virus infection. (2001) (0)
Biliary obstruction due to chronic pancreatitis. (1984) (0)
Perforated duodenal ulcer associated with endoscopy resulting in pancreatic abscess. A case report. (1983) (0)
Treatment of hepatocellular carcinoma (1991) (0)
A novel target enrichment strategy in next-generation sequencing through 7-deaza-dGTP-resistant enzymatic digestion (2020) (0)
Terminology of sclerosing cholangitis. (1982) (0)
Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: Outcomes from the withdrawal phase of the HBRN immune active treatment trial. (2023) (0)
Immunostaining for Hepatitis B Viral Antigens in Liver: Association with Clinical, Biochemical and Virologic Features of Disease. (2023) (0)
Pitfalls in the diagnosis of gestational choriocarcinoma. A case report. (1984) (0)
Liver Disease Due to Alpha‐1 Antitrypsin Deficiency: Are We Surprised That It Is More Complex Than We Thought? (2019) (0)
In-depth serum virome analysis in patients with acute liver failure with indeterminate etiology (2019) (0)
What is the optimal therapy for chronic hepatitis B? (2001) (0)
Chronic hepatitis B. (1995) (0)
ErratumTo: A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables (2013) (0)
Hepatitis B. (2000) (0)
Michael Charles Kew - Frontrunner in Hepatology. (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Adrian M. Di Bisceglie?

Adrian M. Di Bisceglie is affiliated with the following schools: